Works matching IS 11792728 AND DT 2024 AND VI 15

Results: 20

Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 169, doi. 10.2147/LCTT.S492126

By:

Lee, Alexandria TM;
Nagasaka, Misako

Publication type:

Article

Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 149, doi. 10.2147/LCTT.S485320

By:

Shim, Joo Sung;
Kim, Youhyun;
Yuh, Taeho;
Lee, Jii Bum;
Kim, Hye Ryun;
Hong, Min Hee;
Cho, Byoung Chul;
Lim, Sun Min

Publication type:

Article

NRG1 Fusions in NSCLC: Being eNRGy Conscious.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 143, doi. 10.2147/LCTT.S464626

By:

Gupta, Brinda;
Barrett, Laura Gosa;
Liu, Stephen V

Publication type:

Article

Adagrasib in KRYSTAL-12 has Broken the KRAS<sup>G12C</sup> Enigma Code in Non-Small Cell Lung Carcinoma.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 161, doi. 10.2147/LCTT.S490942

By:

Luo, Faustine X;
Arter, Zhaohui Liao

Publication type:

Article

Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 129, doi. 10.2147/LCTT.S478054

By:

Arter, Zhaohui Liao;
Nagasaka, Misako

Publication type:

Article

Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature.

Published in:

2024

By:

Liu, Qian;
Zhang, Jun;
Wei, Mingqin;
Zhou, Xue;
Sun, Hao;
Dong, Youhong;
Zhang, Dongdong

Publication type:

Case Study

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 123, doi. 10.2147/LCTT.S467584

By:

Zhu, Jinlian;
Chen, Jie;
Liu, Wei;
Zhang, Junling;
Gu, Yulan

Publication type:

Article

Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 115, doi. 10.2147/LCTT.S467169

By:

Arter, Zhaohui Liao;
Nagasaka, Misako

Publication type:

Article

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 87, doi. 10.2147/LCTT.S463429

By:

Ou, Sai-Hong Ignatius;
Le, Xiuning;
Nagasaka, Misako;
Reungwetwattana, Thanyanan;
Ahn, Myung-Ju;
Lim, Darren WT;
Santos, Edgardo S;
Shum, Elaine;
Lau, Sally CM;
Lee, Jii Bum;
Calles, Antonio;
Wu, Fengying;
Lopes, Gilberto;
Sriuranpong, Virote;
Tanizaki, Junko;
Horinouchi, Hidehito;
Garassino, Marina C;
Popat, Sanjay;
Besse, Benjamin;
Rosell, Rafael

Publication type:

Article

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 55, doi. 10.2147/LCTT.S455034

By:

González-Cao, Maria;
Cai, Xueting;
Bracht, Jilian Wilhelmina Paulina;
Han, Xuan;
Yang, Yang;
Pedraz-Valdunciel, Carlos;
Morán, Teresa;
García-Corbacho, Javier;
Aguilar, Andrés;
Bernabé, Reyes;
De Marchi, Pedro;
da Silva, Luciane Sussuchi;
Leal, Leticia Ferro;
Reis, Rui Manuel;
Codony-Servat, Jordi;
Jantus-Lewintre, Eloisa;
Molina-Vila, Miguel Angel;
Cao, Peng;
Rosell, Rafael

Publication type:

Article

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 75, doi. 10.2147/LCTT.S460147

By:

Lee, Alexandria TM;
Ou, Sai-Hong Ignatius

Publication type:

Article

ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 81, doi. 10.2147/LCTT.S460870

By:

Lee, Jii Bum;
Ou, Sai-Hong Ignatius

Publication type:

Article

"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834).

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 69, doi. 10.2147/LCTT.S461758

By:

Luo, Faustine X;
Ou, Sai-Hong Ignatius

Publication type:

Article

The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions.

Published in:

2024

By:

Kaakour, Dalia;
Nagasaka, Misako

Publication type:

Case Study

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 41, doi. 10.2147/LCTT.S453974

By:

Brazel, Danielle;
Nagasaka, Misako

Publication type:

Article

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 29, doi. 10.2147/LCTT.S444884

By:

Dou, Xue-Jun;
Ma, Run-Yang;
Ren, De-Wang;
Liu, Qiang;
Yan, Peng

Publication type:

Article

Overcoming Central β-Sheet &num;6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 19, doi. 10.2147/LCTT.S446878

By:

Lee, Alexandria TM;
Ou, Sai-Hong Ignatius

Publication type:

Article

Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 9, doi. 10.2147/LCTT.S446418

By:

Wang, Baofeng;
Wang, Jiang;
Sun, Tongyu;
Ding, Yilin;
Li, Shasha;
Lu, Hengxiao

Publication type:

Article

Overcoming Central β-Sheet &num;6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 19, doi. 10.2147/LCTT.S446878

By:

Lee, Alexandria TM;
Ou, Sai-Hong Ignatius

Publication type:

Article

The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 1, doi. 10.2147/LCTT.S443099

By:

Arter, Zhaohui Liao;
Nagasaka, Misako

Publication type:

Article